Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 11/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.34 |
| ▸ | FEN1 | P39748 | 2/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15462531 | 0.89 | SCN3A (0.37) | SCN3ALIPGGPR119ALOX5APFEN1 | |
| SCHEMBL14815998 | 0.89 | SCN3A (0.37) | SCN3ALIPGGPR119ALOX5APFEN1 | |
| SCHEMBL14815884 | 0.89 | SCN3A (0.40) | NR1H2NR1H3SCN3ALIPGGPR119 | |
| SCHEMBL14815845 | 0.88 | SGK1 (0.36) | TRPV4GPR119 | |
| SCHEMBL14816228 | 0.88 | EPHX2 (0.39) | SCN3ALIPGGPR119ALOX5APFEN1 | |
| SCHEMBL14833334 | 0.88 | EPHX2 (0.39) | SCN3ALIPGGPR119ALOX5APFEN1 | |
| SCHEMBL14815992 | 0.88 | MEN1 (0.45) | TRPV4SCN3ALIPGGPR119ALOX5AP | |
| SCHEMBL15462411 | 0.88 | MEN1 (0.45) | TRPV4SCN3ALIPGGPR119ALOX5AP | |
| SCHEMBL14816013 | 0.87 | NPC1 (0.44) | SCN3AALOX5APFEN1 | |
| SCHEMBL14815839 | 0.86 | KDM4E (0.41) | TRPV4ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648074-B2 | Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers | ABBVIE INC. (US) | 2014-02-11 | — | — | US | claimed |
| US-20130085141-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
| US-8648074-B2 | Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130085141-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085141-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1D, CACNA1A | NR1H2 1896/4885NR1H3 3304/4885TRPV4 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.